Study Cycle. Bachelor or Master.

Study Cycle. Bachelor or equivalent first cycle (EQF level 6) Master or equivalent second cycle (EQF level 7) Doctorate or equivalent third cycle (EQF level 8)

Study Cycle. This part will be filled out by the student according to the academic level of the student. Please read the description at the bottom of the second page of this document. Açıklamalı [MOK2]: 1Field of education: This part will be filled out according to the department that the student enrolled in. The closest option must be selected. To find out the field of education code please visit the link below: xxxxx://xx.xxxxxx.xx/assets/eac/education/tools/iscedf/codes_en.htm Açıklamalı [MOK3]: Please write the faculty and department that you are enrolled in. Açıklamalı [MOK4]: The Receiving Organization/ Enterprise part will be filled out by the host organization. Açıklamalı [MOK5]: The host organization is responsible for filling the Table A Section The traineeship is embedded in the curriculum and upon satisfactory completion of the traineeship, the institution undertakes to: Award …….. .…ECTS credits (or equivalent)11 Give a grade based on: Traineeship certificate ☐ Final report ☐ Interview ☐ Record the traineeship in the trainee's Transcript of Records and Diploma Supplement (or equivalent). Record the traineeship in the trainee's Europass Mobility Document: Yes ☐ No ☐ The traineeship is voluntary and, upon satisfactory completion of the traineeship, the institution undertakes to: Award ECTS credits (or equivalent): Yes ☐ No ☐ If yes, please indicate the number of credits: …. Give a grade: Yes ☐ No ☐ If yes, please indicate if this will be based on: Traineeship certificate ☐ Final report ☐ Interview ☐ Record the traineeship in the trainee's Transcript of Records: Yes ☐ No ☐ Record the traineeship in the trainee's Diploma Supplement (or equivalent). Record the traineeship in the trainee's Europass Mobility Document: Yes ☐ No ☐ Award ECTS credits (or equivalent): Yes ☐ No ☐ If yes, please indicate the number of credits: …. Record the traineeship in the trainee's Europass Mobility Document (highly recommended): Yes ☐ No ☐ Student Mobility for Traineeships Academic Year 2020/2021 Trainee Last name(s) First name(s) Date of birth Nationality1 Gender [Male/Female/ Undefined] Study cycle2 Field of education3 Sending Institution Name Faculty/ Erasmus code4 (if applicable) Address Country Contact person name5; email; phone Department Uskudar University TR ISTANBU46 Altunizade Mah. Haluk Turksoy Sk. No :14 PK :34662 Uskudar Istanbul TURKEY Xxxxx Xxxxx Altınkök xxxxxxx@xxxxxxx.xxx.xx +00000 000 0000 International Relations and Exchange Programs Unit Manager Receiving Orga...

Study Cycle slovně nebo kód dle Annex

Related to Study Cycle

Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.
Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).
Feasibility Study Buyer will, at Buyer's expense and within ____ days from Effective Date ("Feasibility Study Period"), determine whether the Property is suitable, in Buyer's sole and absolute discretion, for ___________________ use. During the Feasibility Study Period, Buyer may conduct a Phase I environmental assessment and any other tests, analyses, surveys and investigations ("Inspections") that Buyer deems necessary to determine to Buyer's satisfaction the Property's engineering, architectural and environmental properties; zoning and zoning restrictions; subdivision statutes; soil and grade; availability of access public roads, water, and other utilities; consistency with local, state and regional growth management plans, availability of permits, government approvals, and licenses; and other inspections that Buyer deems appropriate to determine the Property's suitability for the Buyer's intended use. If the Property must be rezoned, Buyer will obtain the rezoning from the appropriatx xxxernment agencies. Seller will sign all documents Buyer is required to file in connection with development or rezoning approvals. Seller gives Buyer, its agents, contractors and assigns, the right to enter the Property at any time during the Feasibility Study Period for the purpose of conducting inspections; provided, however, that Buyer, its agents, contractors and assigns enter the Property and conduct inspections at their own risk. Buyer will indemnify and hold Seller harmless from xxxxes, damages, costs, claims and expenses of any nature, including attorney's fees, expenses and liability incurred in application for rezoning or related proceedings, and from liability to any person, arising from the conduct of any and all inspections of any work authorized by Buyer. Buyer will not engage in any activity that xxxxx result in a construction lien being filed against the Property without Seller's prior written consent. If this transaction does not close, Buyer will, at Buyer's expense, (1) repair all damages to the Property resulting from the Inspections and return the Property to the condition it was in prior to conduct of the Inspections, and (2) release to Seller all reports and other work generated as a result of the Inspections. Buyer will deliver written notice to Seller prior to the expiration of the Feasibility Study Period of Buyer's determination of whether or not the Properxx xx acceptable. Buyer's failure to comply with this notice requirement will constitute acceptance of the Property as suitable for Buyer's intended use in its "as is" condition. If the Property is unacceptable to Buyer and written notice of this fact is timely delivered to Seller, this Contract will be deemed terminated as of the day after the Feasibility Study period ends and Buyer's deposit(s) will be returned after Escrow Axxxx receives proper authorization form all interested parties.
Evaluation Cycle Goal Setting and Development of the Educator Plan
Case Study Upon Surgi-Vision’s prior written consent in each Instance, Cedara may devise a case-study of any Custom Engineering Services Projects, and may use such case-study for marketing of its engineering services to third parties.
Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.
System Impact Study An assessment by the Transmission Provider of (i) the adequacy of the Transmission System to accommodate a Completed Application, an Interconnection Request or an Upgrade Request, (ii) whether any additional costs may be incurred in order to provide such transmission service or to accommodate an Interconnection Request, and (iii) with respect to an Interconnection Request, an estimated date that an Interconnection Customer’s Customer Facility can be interconnected with the Transmission System and an estimate of the Interconnection Customer’s cost responsibility for the interconnection; and (iv) with respect to an Upgrade Request, the estimated cost of the requested system upgrades or expansion, or of the cost of the system upgrades or expansion, necessary to provide the requested incremental rights.
Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.
Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.
Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

Study Cycle Sample Clauses

Filter & Search

Related Clauses

Related to Study Cycle